- Katrina Williams
- January 10, 2020
- No responses
Merck and FLASCO share the ASCO triple aim of matching the right patient to the right drug at the right time and believe this project can further that objective.
Merck/AstraZeneca developed and shared a non-branded electronic resource that can be utilized by providers and patients, in both English and Spanish, that highlights why BRCA testing in ovarian and breast patients is so important: